- Home
- BLUE
BLUE
bluebird bio Inc.
as 07-26-2024 4:00pm EST
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $5.71 | AVG Volume (30 days): | 5.1M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $5.53 | Next Earning Date: | 08-06-2024 |
| Revenue: | $21,726,000 | Revenue Growth: | 322.60% |
| Revenue Growth (this year): | 901.03% | Revenue Growth (next year): | 239.60% |
Stock Insider Trading Activity of bluebird bio Inc. (BLUE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klima Thomas J | BLUE | See Remarks | Jun 3 '24 | Sell | $0.97 | 3,834 | $3,726.26 | 121,006 | SEC Form 4 |
| Klima Thomas J | BLUE | See Remarks | Mar 1 '24 | Sell | $1.53 | 4,573 | $6,985.71 | 124,840 | SEC Form 4 |
| Colvin Richard A | BLUE | Chief Medical Officer | Mar 1 '24 | Sell | $1.53 | 6,770 | $10,341.85 | 118,368 | SEC Form 4 |
| Obenshain Andrew | BLUE | President and CEO | Mar 1 '24 | Sell | $1.53 | 6,095 | $9,310.72 | 279,998 | SEC Form 4 |
| Vittiglio Joseph | BLUE | Chief Business & Legal Officer | Feb 5 '24 | Sell | $0.90 | 5,217 | $4,708.34 | 44,783 | SEC Form 4 |
| Obenshain Andrew | BLUE | President and CEO | Feb 5 '24 | Sell | $0.90 | 1,879 | $1,695.80 | 286,093 | SEC Form 4 |
| Klima Thomas J | BLUE | See Remarks | Feb 5 '24 | Sell | $0.90 | 2,714 | $2,449.38 | 129,413 | SEC Form 4 |
| Colvin Richard A | BLUE | Chief Medical Officer | Jan 5 '24 | Sell | $1.42 | 597 | $844.76 | 125,138 | SEC Form 4 |
| Obenshain Andrew | BLUE | President and CEO | Jan 5 '24 | Sell | $1.43 | 3,162 | $4,519.76 | 287,972 | SEC Form 4 |
| Krawtschuk Christopher | BLUE | Chief Financial Officer | Dec 6 '23 | Sell | $4.52 | 4,526 | $20,437.15 | 45,474 | SEC Form 4 |
| Obenshain Andrew | BLUE | President and CEO | Nov 3 '23 | Sell | $3.17 | 807 | $2,554.88 | 291,134 | SEC Form 4 |
Latest bluebird bio Inc. News
BLUE Breaking Stock News: Dive into BLUE Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 days ago
HHS gives thumbs down to bluebird’s fertility support programme
Business Wire
23 days ago
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
2 months ago
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
Business Wire
2 months ago
bluebird bio Appoints O. James Sterling as Chief Financial Officer
TipRanks
2 months ago
BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
Motley Fool
2 months ago
Is Bluebird Bio Stock a Buy?
GuruFocus.com
3 months ago
bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...
Zacks
3 months ago
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Compare BLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLUE bluebird bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.